SERA Kacepetan wutah bathi saben saham ing taun lumaku Sera Prognostics, Inc.

Sera Prognostics is integrating preterm birth screening into medical protocols, becoming an indispensable partner for physicians. Data from the GURU.Markets terminal shows proportional EPS growth compared to last year, with the current value standing at 2.60. The company is implementing AI-driven forecasting based on proteomics, while high clinic loyalty is secured by unique biomarkers and the expansion of insurance coverage.

The stable utilization of Sera Prognostics (SERA) diagnostic capacities for preterm birth risk analysis directly impacts the dynamics of net profit allocated per share. This annual earnings per share growth metric captures the percentage deviation of the current EPS from the same period last year, allowing investors to mathematically confirm a reversal in the profitability trend prior to the official publication of financial statements.